Literature DB >> 22301152

The human immunodeficiency virus type 1 Nef and Vpu proteins downregulate the natural killer cell-activating ligand PVR.

Giulia Matusali1, Marina Potestà, Angela Santoni, Cristina Cerboni, Margherita Doria.   

Abstract

The human immunodeficiency virus type 1 (HIV-1) evades the immune responses of natural killer (NK) cells through mechanisms that have been partially deciphered. Here we show that in HIV-1-infected T lymphocytes, the early viral Nef protein downmodulates PVR (CD155, Necl-5), a ligand for the activating receptor DNAM-1 (CD226) expressed by all NK cells, CD8(+) T cells, and other cell types. This novel Nef activity is conserved by Nef proteins of laboratory HIV-1 strains (NL4-3, SF2) and of a patient-derived virus, but it is not maintained by HIV-2. Nef uses the same motifs to downregulate PVR and HLA-I molecules, likely by the same mechanisms. Indeed, as previously demonstrated for HLA-I, Nef reduces the total amounts of cell-associated PVR. Optimal downregulation of cell surface PVR by Nef also requires the presence of the late viral factor Vpu. In line with PVR reduction, the NK cell-mediated lysis of T cells infected by a wild-type but not Nef-deficient virus is virtually abrogated upon blocking of both DNAM-1 and another activating receptor, NKG2D, previously shown to mediate killing of HIV-infected cells. Together, these data demonstrate that the PVR downmodulation by Nef and Vpu is a strategy evolved by HIV-1 to prevent NK cell-mediated lysis of infected cells. The PVR downregulation reported here has the potential to affect the immune responses of other DNAM-1-positive cells besides NK cells and to alter multiple PVR-mediated cellular processes, such as adhesion and migration, and may thus greatly influence HIV-1 pathogenesis.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22301152      PMCID: PMC3318642          DOI: 10.1128/JVI.05788-11

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  64 in total

1.  Human immunodeficiency virus type 1 particles pseudotyped with envelope proteins that fuse at low pH no longer require Nef for optimal infectivity.

Authors:  N Chazal; G Singer; C Aiken; M L Hammarskjöld; D Rekosh
Journal:  J Virol       Date:  2001-04       Impact factor: 5.103

Review 2.  Roles of the NKG2D immunoreceptor and its ligands.

Authors:  David H Raulet
Journal:  Nat Rev Immunol       Date:  2003-10       Impact factor: 53.106

Review 3.  Signals for sorting of transmembrane proteins to endosomes and lysosomes.

Authors:  Juan S Bonifacino; Linton M Traub
Journal:  Annu Rev Biochem       Date:  2003-03-06       Impact factor: 23.643

4.  HIV-1 Nef downregulates MHC-I by a PACS-1- and PI3K-regulated ARF6 endocytic pathway.

Authors:  Anastassia D Blagoveshchenskaya; Laurel Thomas; Sylvain F Feliciangeli; Chien Hui Hung; Gary Thomas
Journal:  Cell       Date:  2002-12-13       Impact factor: 41.582

5.  Cutting edge: CD96 (tactile) promotes NK cell-target cell adhesion by interacting with the poliovirus receptor (CD155).

Authors:  Anja Fuchs; Marina Cella; Emanuele Giurisato; Andrey S Shaw; Marco Colonna
Journal:  J Immunol       Date:  2004-04-01       Impact factor: 5.422

6.  A novel flow cytometric assay for quantitation and multiparametric characterization of cell-mediated cytotoxicity.

Authors:  H Lecoeur; M Février; S Garcia; Y Rivière; M L Gougeon
Journal:  J Immunol Methods       Date:  2001-07-01       Impact factor: 2.303

7.  CD4 and major histocompatibility complex class I downregulation by the human immunodeficiency virus type 1 nef protein in pediatric AIDS progression.

Authors:  Nicoletta Casartelli; Gigliola Di Matteo; Marina Potestà; Paolo Rossi; Margherita Doria
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

8.  Functional characterization of DNAM-1 (CD226) interaction with its ligands PVR (CD155) and nectin-2 (PRR-2/CD112).

Authors:  Satoko Tahara-Hanaoka; Kazuko Shibuya; Yuko Onoda; Hua Zhang; Satoshi Yamazaki; Akitomo Miyamoto; Shin-Ichiro Honda; Lewis L Lanier; Akira Shibuya
Journal:  Int Immunol       Date:  2004-04       Impact factor: 4.823

9.  DNAM-1 and PVR regulate monocyte migration through endothelial junctions.

Authors:  Nicolas Reymond; Anne-Marie Imbert; Elisabeth Devilard; Stéphanie Fabre; Christian Chabannon; Luc Xerri; Catherine Farnarier; Claudia Cantoni; Cristina Bottino; Alessandro Moretta; Patrice Dubreuil; Marc Lopez
Journal:  J Exp Med       Date:  2004-05-10       Impact factor: 14.307

10.  Identification of PVR (CD155) and Nectin-2 (CD112) as cell surface ligands for the human DNAM-1 (CD226) activating molecule.

Authors:  Cristina Bottino; Roberta Castriconi; Daniela Pende; Paola Rivera; Marina Nanni; Barbara Carnemolla; Claudia Cantoni; Jessica Grassi; Stefania Marcenaro; Nicolas Reymond; Massimo Vitale; Lorenzo Moretta; Marc Lopez; Alessandro Moretta
Journal:  J Exp Med       Date:  2003-08-11       Impact factor: 14.307

View more
  72 in total

1.  HIV-1 Vpu Downmodulates ICAM-1 Expression, Resulting in Decreased Killing of Infected CD4+ T Cells by NK Cells.

Authors:  Scott M Sugden; Tram N Q Pham; Éric A Cohen
Journal:  J Virol       Date:  2017-03-29       Impact factor: 5.103

2.  Natural killer cells in HIV controller patients express an activated effector phenotype and do not up-regulate NKp44 on IL-2 stimulation.

Authors:  Francesco Marras; Elena Nicco; Federica Bozzano; Antonio Di Biagio; Chiara Dentone; Emanuele Pontali; Silvia Boni; Maurizio Setti; Giancarlo Orofino; Eugenio Mantia; Valentina Bartolacci; Francesca Bisio; Agostino Riva; Roberto Biassoni; Lorenzo Moretta; Andrea De Maria
Journal:  Proc Natl Acad Sci U S A       Date:  2013-07-01       Impact factor: 11.205

3.  Impaired Downregulation of NKG2D Ligands by Nef Proteins from Elite Controllers Sensitizes HIV-1-Infected Cells to Antibody-Dependent Cellular Cytotoxicity.

Authors:  Nirmin Alsahafi; Jonathan Richard; Jérémie Prévost; Mathieu Coutu; Nathalie Brassard; Matthew S Parsons; Daniel E Kaufmann; Mark Brockman; Andrés Finzi
Journal:  J Virol       Date:  2017-07-27       Impact factor: 5.103

4.  Recognition of nectin-2 by the natural killer cell receptor T cell immunoglobulin and ITIM domain (TIGIT).

Authors:  Felix A Deuss; Benjamin S Gully; Jamie Rossjohn; Richard Berry
Journal:  J Biol Chem       Date:  2017-05-17       Impact factor: 5.157

Review 5.  Natural Killer Cell Memory.

Authors:  Timothy E O'Sullivan; Joseph C Sun; Lewis L Lanier
Journal:  Immunity       Date:  2015-10-20       Impact factor: 31.745

6.  HIV-1 Vpu mediated downregulation of CD155 requires alanine residues 10, 14 and 18 of the transmembrane domain.

Authors:  Sebastian Bolduan; Tatjana Reif; Michael Schindler; Ulrich Schubert
Journal:  Virology       Date:  2014-08-09       Impact factor: 3.616

7.  HIV-1 Nef and Vpu Interfere with L-Selectin (CD62L) Cell Surface Expression To Inhibit Adhesion and Signaling in Infected CD4+ T Lymphocytes.

Authors:  Lia Vassena; Erica Giuliani; Herwig Koppensteiner; Sebastian Bolduan; Michael Schindler; Margherita Doria
Journal:  J Virol       Date:  2015-03-11       Impact factor: 5.103

Review 8.  Innate antiviral immune signaling, viral evasion and modulation by HIV-1.

Authors:  Arjun Rustagi; Michael Gale
Journal:  J Mol Biol       Date:  2013-12-08       Impact factor: 5.469

9.  Primary HIV-1 Strains Use Nef To Downmodulate HLA-E Surface Expression.

Authors:  Thomas van Stigt Thans; Janet I Akko; Annika Niehrs; Wilfredo F Garcia-Beltran; Laura Richert; Christina M Stürzel; Christopher T Ford; Hui Li; Christina Ochsenbauer; John C Kappes; Beatrice H Hahn; Frank Kirchhoff; Glòria Martrus; Daniel Sauter; Marcus Altfeld; Angelique Hölzemer
Journal:  J Virol       Date:  2019-09-30       Impact factor: 5.103

10.  HIV-1 Vpu affects the anterograde transport and the glycosylation pattern of NTB-A.

Authors:  Sebastian Bolduan; Philipp Hubel; Tatjana Reif; Veronika Lodermeyer; Kristin Höhne; Joëlle V Fritz; Daniel Sauter; Frank Kirchhoff; Oliver T Fackler; Michael Schindler; Ulrich Schubert
Journal:  Virology       Date:  2013-03-22       Impact factor: 3.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.